Baker Bros. Advisors (GP) LLC, Director at ALEXION PHARMACEUTICALS, INC. (ALXN), bought 162,259 shares at $83.14 ($13.3M) on 2020-03-18, disclosed to the SEC on 2020-03-18.
Open-market purchase of $13.3M ALXN by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $81.09 | 1,158 | $94K | 0.7% |
| 2 | $81.09 | 1,158 | $94K | 0.7% |
| 3 | $81.09 | 12,815 | $1.0M | 7.8% |
| 4 | $81.09 | 12,815 | $1.0M | 7.8% |
| 5 | $81.47 | 380 | $31K | 0.2% |
| 6 | $81.47 | 4,203 |
| $342K |
| 2.6% |
| 7 | $81.47 | 4,203 | $342K | 2.6% |
| 8 | $81.79 | 25,640 | $2.1M | 15.8% |
| 9 | $81.79 | 2,314 | $189K | 1.4% |
| 10 | $81.79 | 2,314 | $189K | 1.4% |
| 11 | $81.79 | 25,640 | $2.1M | 15.8% |
| 12 | $82.13 | 1,439 | $118K | 0.9% |
| 13 | $82.13 | 1,439 | $118K | 0.9% |
| 14 | $82.13 | 15,928 | $1.3M | 9.8% |
| 15 | $82.13 | 15,928 | $1.3M | 9.8% |
| 16 | $82.92 | 119 | $10K | 0.1% |
| 17 | $82.92 | 1,321 | $110K | 0.8% |
| 18 | $82.92 | 1,321 | $110K | 0.8% |
| 19 | $83.14 | 14,731 | $1.2M | 9.2% |
| 20 | $83.14 | 14,731 | $1.2M | 9.2% |
| 21 | $83.14 | 1,331 | $111K | 0.8% |
| 22 | $83.14 | 1,331 | $111K | 0.8% |
| Total | $82.01 avg | 162,259 | $13.3M | 100% |
| Filing → |
| KOD | BUY | 2026-09-30 | $63.4M | — | Filing → |
| TRDA | BUY | 2025-11-12 | $2.6M | — | Filing → |
| CELC | BUY | 2025-09-10 | $19.1M | — | Filing → |